Skip to content

A multicenter real-world study to evaluate the safety of compound Eucommia ulmoides bone granules

A multicenter real-world study to evaluate the safety of compound Eucommia ulmoides bone granules

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400087317
Enrollment
Unknown
Registered
2024-07-24
Start date
2024-07-26
Completion date
Unknown
Last updated
2024-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis of the knee

Interventions

Observation group:NA

Sponsors

The First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Patients who are clinically accepted to take Compound Eucommia ulmoides Jiangu Granules; (2) Inpatients or outpatients with good compliance and meeting the selection criteria; (3) Patients and their families voluntarily participate in this study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients with purulent and tuberculous arthritis or local soft tissue infection; (2) Patients with severe cardiac, renal, endocrine system diseases or a history of peptic ulcer; (3) pregnant and lactating women; (4) Those who have a history of severe allergies in the past, or are allergic to the drugs used this time; (5) Those who believe that there are other factors that are not suitable for participating in the trial.

Design outcomes

Primary

MeasureTime frame
Adverse events;

Countries

China

Contacts

Public ContactTong Peijian

The First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine

tongpeijian@163.com+86 139 0650 3677

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026